Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9027476 | 0.75 | ABL1 (0.35) | CYP2A6ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL8406829 | 0.75 | ALB (0.41) | LMNAALB | |
| SCHEMBL9751247 | 0.75 | ADRB1 (0.38) | LMNA | |
| SCHEMBL8663124 | 0.75 | ADRB1 (0.38) | LMNA | |
| SCHEMBL18190781 | 0.72 | HRH4 (0.39) | CYP2A6ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL2352863 | 0.69 | SYK (0.33) | ALDH1A1JAK2JAK1TYK2JAK3 | |
| SCHEMBL1444855 | 0.69 | SLC5A2 (0.47) | ALDH1A1LMNACYP3A4 | |
| SCHEMBL2563761 | 0.69 | SLC5A2 (0.47) | ALDH1A1LMNACYP3A4 | |
| SCHEMBL3786766 | 0.69 | SLC5A2 (0.47) | ALDH1A1LMNACYP3A4 | |
| SCHEMBL7024599 | 0.69 | SLC5A2 (0.47) | ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139545-A1 | FORMULATION TO TREAT EAR INFECTION | CHOE WON-TAEK | 2008-06-12 | — | — | US | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1478738-A4 | ANTI-CCR5 ANTIBODY | PROGENICS PHARM INC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| EP-1478738-A1 | ANTI-CCR5 ANTIBODY | PROGENICS PHARMACEUTICALS, INC. (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003072766-A1 | ANTI-CCR5 ANTIBODY | PROGENICS PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | CYP2A6 3700/4885ALDH1A1 1039/4885LMNA 1871/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | CYP2A6 4486/4885ALDH1A1 3047/4885LMNA 541/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | CYP2A6 1273/4885ALDH1A1 3866/4885LMNA 1509/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | CYP2A6 2103/4885ALDH1A1 2112/4885LMNA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.